Balancius™, a unique innovation developed by the alliance of DSM and Novozymes, is the first muramidase (microbial enzyme) designed to degrade and reduce the effects of bacterial debris in the gut in poultry.

The cell wall of Gram (+) and (-) bacteria is mainly composed of peptidoglycans (PGN). The death of bacteria releases PGNs in the gut, which affect gastrointestinal functionality. Balancius™ hydrolyzes PGNs from these debris, preventing their attachment to enterocytes, reducing local inflammation and improving the digestion and absorption of nutrients. The beneficial zootechnical effects observed are an improvement of the feed conversion, meat yield, better litter quality and less pododermatitis.

In more than 50 trials carried out worldwide, studies show an average improvement in feed efficiency of 3%, or for 1 million chickens produced a saving of 125 tonnes of feed.

In Europe, Balancius™ has been authorized since May 2019 in broiler and minor poultry species, and February 2020 in turkey for fattening and all poultry species for breeding.